AMKL	Acute megakaryoblastic leukemia
AML	Acute myeloid leukemia
AML-BFM	Acute Myeloid Leukemia–Berlin Frankfurt Münster
CHAF1B	Chromatin assembly factor 1 subunit B
CHD	Congenital heart disease
CI	Confidence interval
COG	Children’s Oncology Group
DCOG	Dutch Childhood Oncology Group
DIC	Disseminated intravascular coagulation
DS	Down syndrome
DYRK1A	Dual specificity tyrosine phosphorylation regulated kinase 1A
EED	Ectoderm development
EFS	Event-free survival
EP300	E1A binding protein P300
ERG	ETS-related gene
ETS2	ETS proto-oncogene 2
FAB	French–American–British
GM-CSF	Granulocyte–macrophage colony-stimulating factor
HD-AraC	High-dose cytarabine course
HMGN1	High-mobility group nucleosome binding domain 1
HR	High risk
HSA21	Homo Sapiens chromosome 21
HSCs	Hematopoietic stem cells
iPSCs	Induced pluripotent stem cells
KANSL1	KAT8 regulatory NSL complex subunit 1
KDM6A	Lysine demethylase 6A
KMT2C	Lysine methyltransferase 2C
LTS	Life-threatening symptoms
MEP	Megakaryocyte–erythroid progenitors
ML-DS	Myeloid leukemia of Down syndrome
NAT-6	N-acetyltransferase 6
NFAT	Nuclear factor of activated T-cells
NOPHO	Nordic Society for Pediatric Hematology and Oncology
OIDSCS	Oxford Imperial Down Syndrome Cohort Study
OS	Overall survival
PRC2	Polycomb repressive complex 2
RCAN1	Regulator of calcineurin 1
RUNX1	Runt-related transcription factor 1
SON	SON DNA and RNA binding protein
SR	Standard risk
TAM	Transient abnormal myelopoiesis
TET2	Tet methylcytosine dioxygenase 2
TPO	Thrombopoietin
WHO	World Health Organization